Active Biotech AB (publ) (STO:ACTI)
Sweden · Delayed Price · Currency is SEK 5.07
+0.02 (0.40%)
Sep 2, 2026, 5:29 PM CET
Active Biotech AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 43.9 | 65.1 | 27.4 | 36.22 | 41.8 | 53.13 |
Cash & Short-Term Investments | 43.9 | 65.1 | 27.4 | 36.22 | 41.8 | 53.13 |
Cash Growth | 161.31% | 137.63% | -24.36% | -13.35% | -21.34% | 102.70% |
Other Receivables | 2.1 | 1.4 | 9.5 | 1.26 | 0.95 | 1.19 |
Receivables | 2.1 | 1.4 | 9.5 | 1.26 | 0.95 | 1.19 |
Prepaid Expenses | - | 1.08 | 2.32 | 1.24 | 1.38 | 1.53 |
Total Current Assets | 46 | 67.58 | 39.21 | 38.71 | 44.12 | 55.86 |
Property, Plant & Equipment | 1.3 | 2.02 | 3.35 | 4.72 | 6.26 | 0.95 |
Other Intangible Assets | 0.2 | 0.25 | 0.25 | 0.25 | 0.25 | - |
Other Long-Term Assets | 0.4 | 0.38 | 0.38 | 0.38 | 0.38 | 0 |
Total Assets | 47.9 | 70.21 | 43.18 | 44.05 | 51.01 | 56.8 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | - | 4.92 | 1.45 | 3.17 | 3.53 | 2.76 |
Accrued Expenses | - | 7.68 | 5.44 | 5.36 | 6.37 | 5.98 |
Current Portion of Leases | - | 1.61 | 1.65 | 1.55 | 1.61 | 0.76 |
Other Current Liabilities | 10.6 | 0.28 | 0.36 | 0.3 | 0.56 | 0.41 |
Total Current Liabilities | 10.6 | 14.47 | 8.91 | 10.38 | 12.06 | 9.9 |
Long-Term Leases | 0.1 | 0.13 | 1.53 | 3 | 4.43 | 0.23 |
Total Liabilities | 10.7 | 14.6 | 10.44 | 13.38 | 16.49 | 10.13 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 37.2 | 13.61 | 6.35 | 1.87 | 1.37 | 1.13 |
Additional Paid-In Capital | - | 3,562 | 3,509 | 3,472 | 3,431 | 3,386 |
Retained Earnings | - | -3,520 | -3,483 | -3,443 | -3,398 | -3,340 |
Shareholders' Equity | 37.2 | 55.61 | 32.74 | 30.67 | 34.51 | 46.67 |
Total Liabilities & Equity | 47.9 | 70.21 | 43.18 | 44.05 | 51.01 | 56.8 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.1 | 1.74 | 3.18 | 4.55 | 6.04 | 0.99 |
Net Cash (Debt) | 43.8 | 63.36 | 24.21 | 31.67 | 35.76 | 52.15 |
Net Cash Growth | 173.75% | 161.72% | -23.56% | -11.42% | -31.43% | 115.38% |
Net Cash Per Share | 2.14 | 4.70 | 5.76 | 11.66 | 15.30 | 24.38 |
Filing Date Shares Outstanding | 26.36 | 26.36 | 12.3 | 3.62 | 2.65 | 2.18 |
Total Common Shares Outstanding | 26.36 | 26.36 | 10.66 | 3.62 | 2.65 | 2.18 |
Working Capital | 35.4 | 53.11 | 30.3 | 28.33 | 32.06 | 45.95 |
Book Value Per Share | 1.41 | 2.11 | 3.07 | 8.48 | 13.03 | 21.41 |
Tangible Book Value | 37 | 55.37 | 32.5 | 30.42 | 34.27 | 46.67 |
Tangible Book Value Per Share | 1.40 | 2.10 | 3.05 | 8.41 | 12.94 | 21.41 |